Abstract: Novel tumor specific phototherapeutic and photodiagnostic agents are disclosed. The compounds consist of a carbocyanine dye for visualization, photosensitizer for photodynamic treatment, and tumor receptor-avid peptide for site-specific delivery of the probe and phototoxic agent to diseased tissues. A combination of these elements takes full advantage of the unique and efficient properties of each component for an effective patient care management.

Abstract: Cosmetic and dermatological formulations containing at least one UV-sensitive active ingredient have increased UV protection and have the active ingredient stabilized against decomposition through addition of at least one dialkyl naphthalate of the structural formula wherein R1 and R2 are selected independently of one another from the group consisting of branched and unbranched alkyl groups having between 6 and 24 carbon atoms, and at least one emulsifier, selected from the group consisting of phosphate and sulphate emulsifiers.

Abstract: Compositions, optionally heat-activated, methods and kits for protecting keratinous fibers from extrinsic damage or repairing keratinous fibers damaged by extrinsic conditions by applying to keratinous fibers a composition comprising at least one compound chosen from C3 to C5 monosaccharides substituted with at least one C1 to C22 carbon chain, and heating the keratinous fibers.

Abstract: The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids, methods for production thereof, and uses thereof, for a novel ELR-CXC chemokine receptor antagonist.

Abstract: The invention relates to the use of IL6RIL6 chimera in the treatment and prevention of neurological diseases and disorders.

Abstract: Physiologically active PEG-IFN? conjugate having a formula as follows:

Abstract: The invention uses recombinant parvoviruses, and particularly recombinant adeno-associated virus (rAAV) to deliver genes and DNA sequences for gene therapy following manipulation of the therapeutic virus for packaging and transport. The invention delivers therapeutic viral vectors via rAAV affixed to support matrixes (i.e., sutures, surgically implantable materials, grafts, and the like).

Abstract: Human pre-formed xenoantibodies play an important role in the hyperacute rejection response in human xenotransplantation. Disclosed are materials and methods for removing or neutralizing such antibodies. Also disclosed are materials and methods for reducing or eliminating the epitopes in the donor organs that are recognized by such antibodies. Such epitopes are formed as the result of activity by the enzyme ?-1,3 galactosyltransferase. The porcine gene encoding ?-1,3 galactosyltransferase is disclosed, as are materials and methods for inactivating (“knocking out”) the ?-1,3 galactosyltransferase gene in mammalian cells and embryos. Included are nucleic acid constructs useful for inactivating the ?-1,3 galactosyltransferase gene in a target cell. Also disclosed is a novel leukemia inhibitory factor (T-LIF) that is useful for maintenance of embryonic stem cells and primordial germ cells in culture.

Abstract: The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In. particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM?) of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM? allows the use of an immunoenzymatic assay for their detection.

Abstract: Methods for producing biological solutions such as immunoglobulins and in particular anti-D immunoglobulin substantially free of abnormal prion protein resulting therefrom. Specifically provided are methods for aggregation of prions and depth filtration of the biological solution to capture and remove abnormal and if desired, normal prion protein. The prion protein may then be eluted from the depth filter and filter washes and concentrated sufficient for detection at limits currently required by available assays.

Abstract: The invention relates to a recombinant DNA and polypeptide sequence of an immuno-dominant phage particle associated protein from Bartonella bacilliformis. The recombinant protein is easily produced permitting the conduct of more accurate and rapid diagnositic assays for the detection of B. bacilliformis infection with reduced reagent and equipment requirements over that required by currently available methods of diagnosis. The DNA and polypeptide sequence is also useful in vaccine preparations against B. bacilliformis.

Abstract: A method and device for determining a feline immunodeficiency virus infection or vaccination in an animal. The method includes contacting a biological sample from a felid with various FIV polypeptides and determining the binding of antibodies in the sample to the polypeptides. The determination of whether an animal is infected with FIV or has been vaccinated against FIV can be determined by measuring the animal's immune response to an FIV env polypeptide. A device for detecting FIV antibodies is provided.

Abstract: The invention provides compositions containing HCV epitopes, which are recognized by cytotoxic T lymphocytes. Such polypeptides are used in prophylactic vaccines, immunotherapies, and assays to monitor the progress or success of immune interventions. The compositions are optimized to elicit an immune response in a genetically-diverse population of individuals.

Abstract: A novel fusion protein, comprising a receptor-antagonizing domain and a positive immunomodulator domain, characterized, for example, by its ability to block apoptosis and/or inhibit endocrine response, is useful in treating cancer. For example, a human prolactin antagonist-interleukin 2 (hPRLA-IL-2) fusion protein combines apoptosis induction and immuno-therapy to combat cancer in the breast or prostate.

Abstract: The present invention relates to pharmaceutical compositions and dietary supplement comprising yeast cells that can produce a healthful benefit in a subject inflicted with kidney cancer. The biological compositions can be used to retard the growth of kidney cancer cells and/or prolonging the time of survival of the subject. The invention also relates to methods for manufacturing the biological compositions.

Abstract: Chimeric human-bovine parainfluenza viruses (PIVs) are infectious and attenuated in humans and other mammals and useful individually or in combination in vaccine formulations for eliciting an anti-PIV immune response or as vectors for introducing heterologous genes into a host. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete human or bovine PIV “background” genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different PIV. Chimeric human-bovine PIV of the invention include a partial or complete “background” PIV genome or antigenome derived from or patterned after a human or bovine PIV virus combined with one or more heterologous gene(s) or genome segment(s) of a different PIV virus to form the human-bovine chimeric PIV genome or antigenome.

Abstract: Described are DNA sequences encoding an E6 or E7 fusionprotein of HPV, wherein said DNA sequences are characterized by a combination of the following features: original codons are exchanged by codons which lead to an enhanced translation in a mammalian cell, they contain a deletion resulting in the production of a truncated non-functional protein, and they encode a fusionpartner which is a highly immunogenic polypeptide capable of enhancing the immunogenicity of the E6 or E7 protein in the mammalian host. Furthermore, the modified E6 or E7 protein encoded by said DNA sequences as well as expression vectors containing said DNA sequences are described as well as several uses of the these compounds.

Abstract: The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at least one identifying phenotype of the cold-adapted equine influenza virus, such as cold-adaptation, temperature sensitivity, dominant interference, or attenuation. Such viruses are formulated into therapeutic compositions to protect animals from diseases caused by influenza A viruses, and in particular, to protect horses from disease caused by equine influenza virus. The present invention also includes methods to protect animals from diseases caused by influenza A virus utilizing the claimed therapeutic compositions.

Abstract: The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anaemia virus. Specifically, such vaccines contain at least one nucleic acid sequence which is derived from ISAV or synthetically prepared analogues thereof, or substantially homologous sequences. These nucleic acid sequences are transcripted and translated into peptide sequences which are incorporated into a vaccination strategy to induce and immune response to the surface antigens of ISAV and therefore ISAV itself. Therefore both the use of a vaccine against ISAV, and the incorporation of peptide sequences is herein described.

Abstract: The present invention discloses nucleic acid sequences which encode infectious hepatitis C viruses and the use of these sequences, and polypeptides encoded by all or part of these sequences, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.

Abstract: Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis having a variant of recombinant Bacillus anthracis protective antigen (rPA) and a variant of recombinant Bacillus anthracis lethal factor (rLF). These proteins may be expressed separately or as a fusion protein. The recombinant proteins are produced in an avirulent strain of Bacillus anthracis that overproduces the desired antigens. The compositions and methods induce the animal host to produce antibodies against a virulent strain of Bacillus anthracis.

Abstract: The present invention relates to a semi-solid filling medium which comprises a camptothecin derivative; a pharmaceutically acceptable carrier matrix which is a polyglycolized glyceride; and an effective thickening-reducing and stabilizing-promoting amount of one or more pharmaceutically acceptable excipients.

Abstract: New medicaments and compositions having an antiperspirant agent and an antimicrobial agent, and methods based thereof, for control, prevention, amelioration, or treatment of perspiration and topical microbial contamination or infection of skin of the hands, feet, groin, face and other areas of the body, along with reduction or control of symptoms and side effects of such perspiration and microbial contamination or infection, are disclosed. Such medicaments and compositions can be used for various cosmetic, medicinal or pharmaceutical purposes, including control of microbial growth on gloved hands, control of microbial contamination of hands, control of chronic irritation or infection of hands, feet, groin, head, or other areas of skin associated with athletic participation, control of facial acne or other similar conditions, as a cosmetic foundation, or for control of foot odor or excessive foot perspiration.

Abstract: Described for the purpose of application to an inanimate laminar substantially solid surface is a substantially hydrocarbon-free functional substance-providing stick article having consistently-maintained functional composition integrity comprising a stiff, substantially monophasic, thermally-reversible hydrocarbon-free composition consisting essentially of a mixture of: (a) a structural support polymer containing an ester-terminated polyamide and/or at least one tertiary amide-terminated polyamide; (b) a high concentration of a system-compatible functional composition which is one or more of a perfume composition, an insect repellant composition, an animal repellant composition, an anti-microbial composition, an insect attractant composition and/or an air freshener composition; and (c) at least one compatible operativeness organic acid ester and/or metal salt additive which enables the stick, prior to, during and subsequent to application thereof to the inanimate laminar substantially solid surface, to ha

Abstract: A method and device for metered delivery of an insecticidal liquid into a room for the purpose of repelling or killing flying insects, wherein the liquid is ejected in small quantities from a bubble-jet type liquid emanator device at an ambient temperature. The ejected droplets may also be charged to (?1×10?4 C/Kg) by passing the droplets through a static field which will cause the droplets to be attracted to the positive charge which exists across the insects cuticle. Other applications include dispensation of fragrances and air fresheners into a room.

Abstract: A method of making an implantable scaffold for repairing damaged or diseased tissue includes the step of suspending pieces of an extracellular matrix material in a liquid. The extracellular matrix material and the liquid are formed into a mass. The liquid is subsequently driven off so as to form interstices in the mass. The scaffold may further comprise biological agents that promote tissue repair and healing. Porous implantable scaffolds fabricated by such a method are also disclosed.

Abstract: Methods and systems are provided for treating a vascular structure having a defect, for example, a cerebral artery having a weakened wall that has formed an aneurysm. The methods include substantially entrapping a quantity of blood within a vascular defect, and introducing a quantity of a crosslinking agent, for example as a liquid solution, into the entrapped blood. The crosslinking agent is a compound in which each molecule of the compound has at least two nucleophilic-reactive functional groups. The crosslinking agent is allowed to combine with and react with the substantially entrapped blood, and a substantially solid mass made of crosslinked blood is formed within the defect.

Abstract: The present invention relates to the discovery of a transdermal delivery system that can deliver high molecular weight pharmaceuticals and cosmetic agents to skin cells. A novel transdermal delivery system with therapeutic and cosmetic application and methods of use of the foregoing is disclosed.

Abstract: This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.

Abstract: The invention herein relates to a pharmaceutical composition containing loratadine and derivatives thereof which is suitable for use in soft capsule dosage forms. A pharmaceutical composition according to the invention comprises loratadine and derivatives thereof in a pharmaceutically effective amount; and a solvent system comprising a mixture of medium chain fatty acids. The loratadine compositions exhibit good solubility and storage stability while maintaining bioavailability of the drug. The compositions also permit high concentrations of solubilized loratadine per total fill volume and thereby permit the use of smaller capsules to deliver the same dosage of drug.

Abstract: The subject of the invention is an orodispersible solid pharmaceutical form characterized in that it comprises: granules consisting of lactose and starch which have been codried; at least one active substance. The subject of the invention is also the use of codried granules consisting of lactose and starch for the preparation of orodispersible solid pharmaceutical forms.

Abstract: A liquid encapsulant component which contains an active, sensitive encapsulant, such as a live microorganism or an enzyme dissolved or dispersed in a liquid plasticizer is admixed with a plasticizable matrix material. The matrix material is plasticizable by the liquid plasticizer and the encapsulation of the active encapsulant is accomplished at a low temperature and under low shear conditions. The active component is encapsulated and/or embedded in the plasticizable matrix component or material in a continuous process to produce discrete, solid particles. The liquid content of the liquid encapsulant component provides substantially all or completely all of the liquid plasticizer needed to plasticize the matrix component to obtain a formable, extrudable, cuttable, mixture or dough. Removal of liquid plasticizer prior to extrusion is not needed to adjust the viscosity of the mixture for formability.

Abstract: A new method is described for the treatment of cancer. In one alternative, the method utilizes two main compositions. The first composition is Soma, a healing herb described in the Rig Veda, the sacred scriptures of the Hindus. The second composition is a composite of plant-derived substances and a mineral. When they are administered to cancer patients following the recommended therapeutic regimen, regression of the cancer results. Alternatively, the second composition can be used alone.

Abstract: The treatment of ungual and subungual diseases is disclosed.

Abstract: An insect repellent composition containing citronella oil, D-limonene, 2 or more synergists, and 3 or more essential oils as the active ingredients. The preferred essential oils are geranium oil, rosemary oil and peppermint oil, but other essential oils may be used. In the preferred embodiment the synergists are aldehyde C-14 and aldehyde C-18. As desired, vanillin may be used as a stabilizer, and fragrances, fragrance enhancers and surfactants may be utilized.

Abstract: A nutritional, olive-oil based, at least semi-solid product for oral intake and for topical application, the product including: (a) an olive oil; (b) an omega-3 fatty acid source, and (c) an emulsifier, the components being intimately mixed so as to form the at least semi-solid product, and wherein a Total Water Content (TWC) within the product is within a range of 0.25% to 3%, by weight.

Abstract: Compositions and methods of inhibiting tumor cell growth and treating and preventing cancer are provided based on administration of an orange peel extract either alone or in combination with other phytochemicals.

Abstract: The invention relates generally to an aspirin formulation which may comprise additional vitamins, minerals, herbs and supplements and methods for using the same for maintaining cardiovascular health. The aspirin formulation may comprise supplements such as vitamin B6, vitamin B12, folic acid, arginine and garlic. The invention also encompasses methods for maintaining healthy blood pressure and cholesterol levels with the aspirin formulation described herein.

Abstract: A method for treating mouth ulcers (canker sores/aphthous ulcers) with licorice extract oral patches to speed healing and relieve pain. If licorice extract is applied to a mouth ulcer using an adhesive oral patch that delivers the medication for at least 30 minutes and the patches are used for at least two or more hours per day, the method reduces the healing times from typically 10–14 days to typically 2 days. The licorice extract patches also quickly reduces canker sore pain and, if used before commencing a meal, reduces pain during the meal. A fully dissolving patch with licorice extract and collagen is disclosed.

Abstract: Pharmaceutical and/or cosmetic compositions for the treatment and the prevention of scalp disorders, containing as active components extracts of Serenoa repens and of Vitis vinifera.

Abstract: A meat product or a processed meat product coated with a film of curdlan gel is prepared.

Abstract: Disclosed is a viscous oil product made by combining an oil or oil-containing product with a crystallizing agent, moderately heating the mixture and allowing the mixture to cool, forming lamellar liquid crystals. A crystal stabilizing agent is also disclosed. A uniquely healthy and palatable manner of providing essential fatty acids for consumption is disclosed.

Abstract: An improved method for increasing the dispersibility of cocoa powder which has been treated with liquid solvent extraction procedures to reduce fat content. A dispersing agent such as lecithin is added to wet cocoa mass comprising remaining cocoa butter and remaining solvent from the liquid extraction. The residual solvent improves the uniformity of mixing between the cocoa mass and the dispersing agent.

Abstract: Coatings for implantable medical devices, such as stents, and methods of coating the devices are disclosed. The method includes forming a coating by plasma polymerization of a monomer or a blend of monomers.

Abstract: A method of film deposition in a sub-atmospheric chemical vapor deposition (CVD) process includes (a) providing a model for sub-atmospheric CVD deposition of a film that identifies one or more film properties of the film and at least one deposition model variable that correlates with the one or more film properties; (b) depositing a film onto a wafer using a first deposition recipe comprising at least one deposition recipe parameter that corresponds to the at least one deposition variable; (c) measuring a film property of at least one of said one or more film properties for the deposited film of step (b); (d) calculating an updated deposition model based upon the measured film property of step (c) and the model of step (a); and (e) calculating an updated deposition recipe based upon the updated model of step (d) to maintain a target film property. The method can be used to provide feedback to a plurality of deposition chambers or to control a film property other than film thickness.

Abstract: The present invention provides unique methods of coating and novel coatings for MEMS devices. In general a two step process includes the coating of a first silane onto a substrate surface followed by a second treatment with or without a second silane and elevated temperatures.

Abstract: A thermosensitive stencil paper having a thermoplastic resin film and a porous resin layer which is provided on the thermoplastic resin film by coating a porous resin layer formation coating liquid including a water-in-oil emulsion of a resin on the thermoplastic resin film and drying the coating liquid. In addition, the method of producing the above-mentioned thermosensitive stencil paper is also disclosed.

Abstract: An optical member (for example, optical fiber) is dipped in a coating solution having a film forming material dissolved therein to form an antireflection film on the end surface of the optical member. When the optical member is pulled up from the coating solution, the angle formed by the level of the coating solution and the end surface of the optical member, or the pulling speed is varied to adjust the film thickness or reflectance of the antireflection film to be formed on the end surface of the optical member. The film forming material is a fluorine-containing compound. The antireflection film is formed by dipping. The film thickness of the antireflection film is uneven.

Abstract: The invention relates to devices for the treatment of heart disease and particularly to endo-arterial prostheses, which are commonly called stents. More particularly, the invention relates to methods of manufacturing and coating stents utilizing thermal spray processing (TSP). In one aspect the invention involves the use of TSP for the manufacture of fine grained tubing for subsequent use as a stent or other tubular or ring-based implant, or the manufacture of intermediate sized tubing that may then be drawn to final size tubing and for the coating of a stent. An average grain size of less than 64 microns is achieved by the invention resulting in a stent having an annular wall average thickness of about eight or more grains.

Abstract: An object of the present invention is to provide an excellent process for production of a surface-treated particulate water-absorbent resin wherein the process adopts a surface-treatment process that can enhance the properties (which the water-absorbent resin is desired to have) to extremely high levels, and also can solve the prior problems in such as safety, and further can sufficiently carry out the treatment even at a reaction temperature near room temperature. As a means of achieving this object, the process according to the present invention for production of a surface-treated particulate water-absorbent resin is characterized by comprising the steps of: adding a treating liquid to a particulate water-absorbent resin as a base polymer, wherein the treating liquid contains a radically polymerizable compound; and then irradiating the particulate water-absorbent resin with active energy rays while fluidizing the particulate water-absorbent resin, thereby surface-treating it.